Peptic ulcer and NSAIDs
| dc.contributor.author | Salem, Fares | |
| dc.date.accessioned | 2019-04-20T10:43:58Z | |
| dc.date.available | 2019-04-20T10:43:58Z | |
| dc.date.issued | 2018-06-28 | |
| dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/784 | |
| dc.description | Gastroduodenal ulceration and bleeding are the major limitations to the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The development of safer NSAIDs or of effective therapies for the prevention of the adverse effects of existing NSAIDs requires a better understanding of the pathogenesis of NSAID-induced ulcer disease. NSAIDs can cause damage to the gastroduodenal mucosa via several mechanisms, including the topical irritant effect of these drugs on the epithelium, impairment of the barrier properties of the mucosa, suppression of gastric prostaglandin synthesis, reduction of gastric mucosal blood flow and interference with the repair of superficial injury | en_US |
| dc.description.abstract | Non-steroidal anti-inflammatory drugs including low-dose aspirin are some of the most commonly used medicines. They are associated with gastrointestinal mucosal injury. Before prescribing, it is important to assess the patient’s gastrointestinal risk factors such as age and history of peptic ulcers. So this report will discuss the relation between peptic ulcer and NSAIDs | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Peptic ulcer and NSAIDs | en_US |
| dc.type | Other | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Attribution 3.0 United States